During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...
The analysis included hormone receptor and HER2/neu status to define subtypes: HR+ HER2+, HR+ HER2−, HR− HER2+, and HR− HER2− ...
The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...
Scientists at Huntsman Cancer Institute at the University of Utah (the U), the National Cancer Institute-designated cancer ...
SurvivorNet on MSN6d
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of KisqaliThe Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...
Scientists at Huntsman Cancer Institute at the University of Utah (the U), the National Cancer Institute-designated cancer ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Groups Develop Request for Proposals for Research Grants Focused on Lung Cancers Harboring HER2 Mutations and/or Other HER2 Alterations This collaboration seeks to address important mechanistic ...
Researchers have developed a new mechanism for predicting the aggressiveness of triple-negative breast cancer (TNBC). This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback